Publication:
Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Simple item page
dc.contributor.authorKilickap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorGumus, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorTurk, H. M.
dc.contributor.authorCicin, I.
dc.contributor.authorBentsion, D.
dc.contributor.authorGladkov, O.
dc.contributor.authorClingan, P.
dc.contributor.authorSriuranpong, V.
dc.contributor.authorRizvi, N.
dc.contributor.authorLi, S.
dc.contributor.authorLee, S.
dc.contributor.authorMakharadze, T.
dc.contributor.authorPaydas, S.
dc.contributor.authorNechaeva, M.
dc.contributor.authorSeebach, F.
dc.contributor.authorWeinreich, D. M.
dc.contributor.authorYancopoulos, G. D.
dc.contributor.authorGullo, G.
dc.contributor.authorLowy, I.
dc.contributor.authorRietschel, P.
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.date.accessioned2021-05-04T20:59:07Z
dc.date.available2021-05-04T20:59:07Z
dc.date.issued2021-03-01T00:00:00Z
dc.identifier.citationKilickap S., Sezer A., Gumus M., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.3, 2021
dc.identifier.urihttp://hdl.handle.net/20.500.12645/28836
dc.identifier.wosWOS:000631349600072
dc.titleClinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
dc.typeArticle
dspace.entity.typePublication
local.avesis.id72070c97-9094-4ed3-8ded-cf22531b3841
local.indexed.atWOS
local.publication.isinternational1
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery1b3a1540-7e57-405d-8a9d-f926d17dcc29

Files

Collections

Yayınlar - Eserler